COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss. (2017)
Attributed to:
MICA: Immunotherapy for oral cancer prevention and treatment
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.ejca.2017.09.033
PubMed Identifier: 29128692
Publication URI: http://europepmc.org/abstract/MED/29128692
Type: Journal Article/Review
Volume: 87
Parent Publication: European journal of cancer (Oxford, England : 1990)
ISSN: 0959-8049